Newsroom
For media inquiries, please contact 340B Health Senior Director of Communications David Glendinning at david.glendinning@340bhealth.org or 202-536-2289.
-
STATEMENT ON APPROVAL OF 340B ELIGIBILITY PROTECTIONS FOR SAFETY-NET HOSPITALS ON THE COVID FRONT LINES
-
STATEMENT ON NEW DIRECTOR OF HRSA OFFICE OF PHARMACY AFFAIRS
-
STATEMENT ON FEDERAL COURT DECISION IN ASTRAZENECA’S 340B COMMUNITY PHARMACY LAWSUIT
-
STATEMENT ON GLAXOSMITHKLINE RESTRICTING 340B DISCOUNTS THROUGH COMMUNITY-BASED PHARMACIES
-
Safety net hospitals report growing financial hit from loss of 340B drug discounts
-
UNLAWFUL DRUG COMPANY LIMITS ON 340B PRICING ARE CAUSING BIG LOSSES FOR SAFETY-NET HOSPITALS
-
Not cheaper by the dozen: Bristol Myers becomes the 12th pharma company to restrict 340B sales
-
STATEMENT ON BRISTOL MYERS SQUIBB RESTRICTING 340B DISCOUNTS THROUGH COMMUNITY-BASED PHARMACIES
-
STATEMENT ON ABBVIE RESTRICTING 340B DISCOUNTS THROUGH COMMUNITY-BASED PHARMACIES
-
340B HEALTH PRAISES GOVERNMENT APPEALS OF COURT DECISIONS ON COMMUNITY PHARMACIES
-
MORE THAN 800 HOSPITALS URGE GOVERNMENT TO APPEAL COURT DECISION ON 340B COMMUNITY PHARMACIES
-
STATEMENT ON AMGEN RESTRICTING 340B DISCOUNTS THROUGH COMMUNITY-BASED PHARMACIES